Mycophenolate monitoring in liver, thoracic, pancreas, and small bowel transplantation: A consensus report

Transplantation Reviews

Volumn 25, Issue 2, 2011, Pages 65-77

  Cantarovich, Marcelo ^a   Brown, Nigel W ^b   Ensom, Mary H H ^c   Jain, Ashok ^d   Kuypers, Dirk R J ^e   Gelder, Teun Van ^f   Tredger, J Michael ^b  

^a MCGILL UNIVERSITY HEALTH CENTRE   (Canada)

^b KING'S COLLEGE LONDON   (United Kingdom)

^c UNIVERSITY OF BRITISH COLUMBIA   (Canada)

^d TEMPLE UNIVERSITY SCHOOL OF MEDICINE   (United States)

^e UNIVERSITY HOSPITALS LEUVEN   (Belgium)

^f ERASMUS MEDICAL CENTER   (Netherlands)

Author keywords

[No Author keywords available]

Indexed keywords

AZATHIOPRINE; BASILIXIMAB; CALCINEURIN INHIBITOR; CORTICOSTEROID; CYCLOSPORIN A; DACLIZUMAB; DRUG METABOLITE; MULTIDRUG RESISTANCE PROTEIN 2; MYCOPHENOLIC ACID; MYCOPHENOLIC ACID 2 MORPHOLINOETHYL ESTER; MYOFORTIC; PROTON PUMP INHIBITOR; RAPAMYCIN; STEROID; TACROLIMUS; THYMOCYTE ANTIBODY; UNCLASSIFIED DRUG; VALPROIC ACID;

ACUTE GRAFT REJECTION; ANEMIA; CARDIOVASCULAR RISK; CIRCADIAN RHYTHM; DIARRHEA; DRUG BIOAVAILABILITY; DRUG BLOOD LEVEL; DRUG EFFICACY; DRUG EXPOSURE; DRUG MONITORING; DRUG SENSITIVITY; DRUG WITHDRAWAL; GASTROINTESTINAL SYMPTOM; GENETIC POLYMORPHISM; GRAFT RECIPIENT; HEMATOPOIETIC STEM CELL TRANSPLANTATION; HUMAN; INCIDENCE; INFECTION; INTESTINAL DYSMOTILITY; INTESTINE TRANSPLANTATION; KIDNEY DISEASE; KIDNEY FUNCTION; LEUKOPENIA; LIVER CIRRHOSIS; LIVER DYSFUNCTION; LIVER TRANSPLANTATION; LOW DRUG DOSE; LUNG TRANSPLANTATION; MONOTHERAPY; MORTALITY; MULTICENTER STUDY (TOPIC); NAUSEA; PANCREAS TRANSPLANTATION; PHARMACOGENOMICS; RANDOMIZED CONTROLLED TRIAL (TOPIC); REVIEW; TREATMENT OUTCOME; VOMITING;

EID: 79953720823     PISSN: 0955470X     EISSN: None     Source Type: Journal    
DOI: 10.1016/j.trre.2010.12.001     Document Type: Review

References (138)

1. Kaufmann D.B., Shapiro R., Lucey M.R., et al. Immunosuppression: practice and trends. Am J Transplant 2004, 4:38-53.
2. Weimert N.A., DeRotte M., Alloway R.D., et al. Monitoring of inosine monophosphate dehydrogenase activity as a biomarker for mycophenolic acid effect: potential clinical implications. Ther Drug Monit 2007, 29:141-149.
3. Klupp J., Pfitzmann, Langrehr J.M., Neuhaus P. Indications of mycophenolate mofetil in liver transplantation. Transplantation 2005, 80:S142-S146.
4. Hoffman-La Roche Ltd CellCept Prescribing information Accessed 23/2/2010. http://www.gene.com/gene/products/information/cellcept/pdf/pi.pdf.
5. Staatz C.E., Tett S.E. Clinical pharmacokinetics and pharmacodynamics of mycophenolate in solid organ transplant recipients. Clin Pharmacokinet 2007, 46:13-58.
6. Kuypers D.R.J., Le Meur Y., Cantarovich M., et al. Consensus report on therapeutic drug monitoring of mycophenolic acid in solid organ transplantation. Clin J Am Soc Nephrol 2010, 5:341-358.
7. Hiwarkar P., Shaw B.E., Tredger J.M., et al. Mycophenolate mofetil in the treatment of graft versus host disease-the clinical value of measuring mycophenolic acid levels and its relationship with serum albumin concentrations. Clin Transplant 2010, [e-print 26/2/2010]. 10.1111/j1399-0012.2010.01226x.
8. Wiesner R., Rabkin J., Klintmalm G., et al. A randomized double-blind comparative study of mycophenolate mofetil and azathioprine in combination with cyclosporine and corticosteroids in primary liver transplant recipients. Liver Transpl 2001, 7:442-450.
9. McDiarmid S.V. Mycophenolate mofetil in liver transplantation. Clin Transplant 1996, 10:140-145.
10. Jain A., Sharma R., Ryan C., et al. Potential immunological advantage of intravenous mycophenolate mofetil with tacrolimus and steroids in primary deceased donor liver transplantation and live donor liver transplantation without antibody induction. Liver Transpl 2008, 14:202-209.
11. Kobashigawa J., Miller L., Renlund D., et al. A randomized active-controlled trial of mycophenolate mofetil in heart transplant recipients. Mycophenolate Mofetil Investigators. Transplantation 1998, 66:507-515.
12. Zuckermann A., Klepetko W., Birsan T., et al. Comparison between mycophenolate mofetil- and azathioprine-based immunosuppressions in clinical lung transplantation. J Heart Lung Transplant 1999, 18:432-440.
13. Ringe B., Braun F., Schutz E., et al. A novel management strategy of steroid-free immunosuppression after liver transplantation: efficacy and safety of tacrolimus and mycophenolate mofetil. Transplantation 2001, 71:508-515.
14. Junge G., Neuhaus R., Schewior L., et al. Withdrawal of steroids: a randomized prospective study of prednisone and tacrolimus versus mycophenolate mofetil and tacrolimus in liver transplant recipients with autoimmune hepatitis. Transplant Proc 2005, 37:1695-1696.
15. Marubashi S., Dono K., Nagano H., et al. Steroid-free living donor liver transplantation in adults: impact on hepatitis C recurrence. Clin Transplant 2009, 23:904-913.
16. Reggiani P., Arru M., Regazzi M., et al. A "steroid-free" tacrolimus and low-dose mycophenolate mofetil primary immunosuppression does not prevent early acute rejection after liver transplantation. Transplant Proc 2005, 37:1697-1699.
17. Mehra M.R., Uber P.A., Park M.H., et al. Corticosteroid weaning in the tacrolimus and mycophenolate era in heart transplantation: clinical and neurohormonal benefits. Transplant Proc 2004, 36:3152-3155.
18. Ojo A.O., Held P.J., Port F.K., et al. Chronic renal failure after transplantation of a nonrenal organ. N Engl J Med 2003, 349:931-940.
19. Kim J.Y., Akalin E., Dikman S., et al. The variable pathology of kidney disease after liver transplantation. Transplantation 2010, 89:215-221.
20. Schlitt H.J., Barkmann A., Böker K.H.W., et al. Replacement of calcineurin inhibitors with mycophenolate mofetil in liver-transplant patients with renal dysfunction: a randomised controlled study. Lancet 2001, 357:587-591.
21. Pageaux G.P., Rostaing L., Calmus Y., et al. Mycophenolate mofetil in combination with reduction of calcineurin inhibitors for chronic renal dysfunction after liver transplantation. Liver Transpl 2006, 12:1755-1760.
22. Cicinnati V.R., Yu Z., Klein C.G., et al. Clinical trial: switch to combined mycophenolate mofetil and minimal dose calcineurin inhibitor in stable liver transplant patients-assessment of renal and allograft function, cardiovascular risk factors and immune monitoring. Aliment Pharmacol Ther 2007, 26:1195-1208.
23. Herrero J.I., Quiroga J., Sangro B., et al. Conversion of liver transplant recipients on cyclosporine with renal impairment to mycophenolate mofetil. Liver Transpl Surg 1999, 5:414-420.
24. Aw M.M., Samaroo B., Baker A., et al. Calcineurin-inhibitor related nephrotoxicity-reversibility in pediatric liver transplant recipients. Transplantation 2001, 72:746-749.
25. Cantarovich M., Tzimas G.N., Barkun J., et al. Efficacy of mycophenolate mofetil combined with very low-dose cyclosporine microemulsion in long-term liver-transplant patients with liver dysfunction. Transplantation 2003, 76:98-102.
26. Raimondo M.L., Dagher L., Papatheodoridis G.V., et al. Long-term mycophenolate mofetil monotherapy in combination with calcineurin inhibitors for chronic renal dysfunction after liver transplantation. Transplantation 2003, 75:186-190.
27. Planas J.M.M., Martinez V.C.M., Gonzalez E.R., et al. Mycophenolate mofetil can be used as monotherapy late after liver transplantation. Am J Transplant 2004, 4:1650-1655.
28. Jain A., Venkataramanan R., Eghtesad B., et al. Long-term outcome of adding mycophenolate mofetil to tacrolimus for nephrotoxicity following liver transplantation. Transplantation 2005, 80:859-864.
29. Pierini A., Mirabella S., Brunati A., et al. Mycophenolate mofetil monotherapy in liver transplantation. Transplant Proc 2005, 37:2614-2615.
30. De Meester J.M., van Vlem B., Walravens M., et al. Preservation of renal function after heart transplantation: initial single-center experience with sirolimus. Transplant Proc 2005, 37:1835-1838.
31. Reich D.J., Clavien P.A., Hodge E.E., et al. Mycophenolate mofetil for renal dysfunction in liver transplant recipients on cyclosporine or tacrolimus: randomized, prospective, multicenter pilot study results. Transplantation 2005, 80:18-25.
32. Bilbao I., Castells L., Rojas L., et al. Immunosuppression based on mycophenolate mofetil in stable liver transplanted patients. Int Immunopharmacol 2006, 6:1977-1983.
33. Orlando G., Baiocchi L., Cardillo A., et al. Switch to 1.5 grams MMF monotherapy for CNI-related toxicity in liver transplantation is safe and improves renal function, dyslipidemia, and hypertension. Liver Transpl 2007, 13:46-54.
34. Beckebaum S., Klein C.G., Sotiropoulos G.C., et al. Combined mycophenolate mofetil and minimal dose calcineurin inhibitor therapy in liver transplant patients: clinical results of a prospective randomized study. Transplant Proc 2009, 41:2567-2569.
35. Biselli M., Vitale G., Gramenzi A., et al. Two year mycophenolate mofetil plus low-dose calcineurin inhibitor for renal dysfunction after liver transplant. Clin Transplant 2009, 23:191-198.
36. Dharancy S., Lannelli A., Hulin A., et al. Mycophenolate mofetil monotherapy for severe side effects of calcineurin inhibitors following liver transplantation. Am J Transplant 2009, 9:610-613.
37. Manrique A., Jimenez A., Jimenez C., et al. Mycophenolate mofetil monotherapy in patients who underwent liver transplantation for hepatitis C cirrhosis. Transplant Proc 2008, 40:2962-2964.
38. Neuberger J., Mamelok R.D., Neuhaus P., et al. Delayed introduction of reduced-dose tacrolimus and renal function in liver transplantation: the ReSpECT study. Am J Transplant 2009, 9:327-336.
39. Evans H.M., McKiernan P.J., Kelly D.A. Mycophenolate mofetil for renal dysfunction after pediatric liver transplantation. Transplantation 2005, 79:1575-1580.
40. Fairbanks K.D., Thuluvath P.J. Mycophenolate mofetil monotherapy in liver transplant recipients: a single center experience. Liver Transpl 2004, 10:1189-1194.
41. Stewart S.F., Hudson M., Talbot D., et al. Mycophenolate mofetil monotherapy in liver transplantation. Lancet 2001, 357:609-610.
42. Chang G.J., Mahanty H.D., Quan D., et al. Experience with the use of sirolimus in liver transplantation-use in patients for whom calcineurin inhibitors are contraindicated. Liver Transpl 2000, 6:734-740.
43. Kniepeiss D., Iberer F., Schaffellner S., et al. Nonnephrotoxic immunosuppression in patients after liver transplantation. Int Immunopharmacol 2005, 5:133-136.
44. Sanchez E.Q., Martin A.P., Ikegami T., et al. Sirolimus conversion after liver transplantation: improvement in measured glomerular filtration rate after 2 years. Transplant Proc 2005, 37:4416-4423.
45. Yang Y.J., Chen D.Z., Li L.X., et al. Sirolimus-based immunosuppressive therapy in liver transplant recipient with tacrolimus-related chronic renal insufficiency. Transplant Proc 2008, 40:1541-1544.
46. Yoshida E.M., Marotta P.J., Greig P.D., et al. Evaluation of renal function in liver transplant recipients receiving daclizumab, mycophenolate mofetil and a delayed low dose tacrolimus regimen versus a standard dose tacrolimus and mycophenolate mofetil regimen: a multicentre randomized clinical trial. Liver Transpl 2005, 11:1064-1072.
47. DuBay D., Smith R.J., Qiu K.G., et al. Sirolimus in liver transplant recipients with renal dysfunction offers no advantage over low-dose calcineurin inhibitor regimens. Liver Transpl 2008, 14:651-659.
48. Morard I., Dumortier J., Spahr L., et al. Conversion to sirolimus-based immunosuppression in maintenance liver transplantation patients. Liver Transpl 2007, 13:658-664.
49. Sanchez E.Q., Melton L.B., Chinnakotla S., et al. Predicting renal failure after liver transplantation from measured glomerular filtration rate: review of up to 15 years of follow-up. Transplantation 2010, 89:232-235.
50. Gleissner C.A., Doesch A., Ehlermann P., et al. Cyclosporine withdrawal improves renal function in heart transplant patients on reduced-dose cyclosporine therapy. Am J Transplant 2006, 6:2750-2758.
51. Åberg F., Jula A., Höckerstedt K., et al. Cardiovascular risk profile of patients with acute liver failure after liver transplantation when compared with the general population. Transplantation 2010, 89:61-68.
52. Gerhardt T., Terjung B., Knipper P., et al. Renal impairment after liver transplantation-a pilot trial of calcineurin inhibitor-free versus calcineurin inhibitor sparing immunosuppression in patients with mildly impaired renal function after liver transplantation. Eur J Med Res 2009, 14:210-215.
53. Gavlik A., Goldberg M.G., Tsaroucha A., et al. Mycophenolate mofetil rescue therapy in liver transplant recipients. Transplant Proc 1997, 29:549-552.
54. Barrera-Pulido L., Álamo Martinez J.M., Pareja Ciuró F., et al. Efficacy and safety of mycophenolate mofetil monotherapy in liver transplant patients with renal failure induced by calcineurin inhibitors. Transplant Proc 2008, 40:2985-2987.
55. Wierzbicka A., Pawlowska J., Socha P., et al. Lipid, carbohydrate metabolism, and antioxidant status in children after liver transplantation. Transplant Proc 2007, 39:1523-1525.
56. Parfitt J.R., Jayakumar S., Driman D.K. Mycophenolate mofetil-related gastrointestinal mucosal injury: variable injury patterns, including graft-versus-host disease-like changes. Am J Surg Pathol 2008, 32:1367-1372.
57. Delacruz V., Weppler D., Island E., et al. Mycophenolate mofetil-related gastrointestinal mucosal injury in multivisceral transplantation. Transplant Proc 2010, 42:82-84.
58. Groetzner J., Kaczmarek I., Landwehr P., et al. Renal recovery after conversion to a calcineurin inhibitor-free immunosuppression in late cardiac transplant recipients. Eur J Cardiothorac Surg 2004, 25:333-341.
59. Lyster H., Panicker G., Leaver N., et al. Initial experience with sirolimus and mycophenolate mofetil for renal rescue from cyclosporine nephrotoxicity after heart transplantation. Transplant Proc 2004, 36:3167-3170.
60. Trösch F., Rothenburger M., Schneider M., et al. First experience with rapamycin-based immunosuppression to improve kidney function after heart transplantation. Thorac Cardiovasc Surg 2004, 52:163-168.
61. Cabezón S., Lage E., Hinojosa R., et al. Sirolimus improves renal function in cardiac transplantation. Transplant Proc 2005, 37:1546-1547.
62. Nure E., Magalini S.C., Frongillo F., et al. Enteric-coated mycophenolate sodium: one-way conversion from mycophenolate mofetil and de novo use in stable liver transplant recipients. Transplant Proc 2009, 41:1290-1292.
63. Robaeys G., Cassiman D., Verslype C., et al. Successful conversion from mycophenolate mofetil to enteric-coated mycophenolate sodium (Myfortic) in liver transplantation patients with gastrointestinal side effects. Transplant Proc 2009, 41:610-613.
64. Barrera-Pulido L., Alamo-Martinez J.M., Marin-Gomez L.M., et al. Switching from mycophenolate mofetil to enteric-coated mycophenolate sodium in liver transplant patients with gastrointestinal complications. Transplant Proc 2009, 41:2192-2194.
65. Doria C., Ramirez C.B., Frank A.M., et al. Use of enteric-coated mycophenolate sodium in liver transplant patients with intestinal intolerance caused by mycophenolate mofetil. Clin Transplant 2009, 23:882-886.
66. Grasser B., Iberer F., Schaffellner S., et al. Trough level-guided mycophenolate mofetil rejection prophylaxis in liver transplantation. Transplant Proc 2001, 33:2154-2156.
67. Tredger J.M., Brown N.W., Adams J.E., et al. Monitoring mycophenolate in liver transplant recipients: towards a therapeutic range. Liver Transpl 2004, 10:492-502.
68. Brunet M., Cirera I., Martorell J., et al. Sequential determination of pharmacokinetics and pharmacodynamics of mycophenolic acid in liver transplant patients treated with mycophenolate mofetil. Transplantation 2006, 81:541-546.
69. Chen H., Chen E., Mao A., et al. Validation of limited sampling strategy for the estimation of mycophenolic acid exposure in Chinese adult liver transplant recipients. Liver Transpl 2008, 13:1684-1693.
70. Hwang S., Lee S.G., Ahn C.S., et al. A clinical assessment of mycophenolate drug monitoring after liver transplantation. Clin Transplant 2010, 24:E35-E42.
71. Yamani M.H., Starling R.C., Goormastic M., et al. The impact of routine mycophenolate mofetil drug monitoring on the treatment of cardiac allograft rejection. Transplantation 2000, 69:2326-2330.
72. Meiser B.M., Pfeiffer M., Schmidt D., et al. Combination therapy with tacrolimus and mycophenolate mofetil following cardiac transplantation: importance of mycophenolic acid therapeutic drug monitoring. J Heart Lung Transplant 1999, 18:143-149.
73. Hesse C.J., Vantrimpont P., Van Riemsdijk-van Overbeeke I.C., et al. The value of routine monitoring of mycophenolic acid plasma levels after clinical heart transplantation. Transplant Proc 2001, 33:2163-2164.
74. DeNofrio D., Loh E., Kao A., et al. Mycophenolic acid concentrations are associated with cardiac allograft rejection. J Heart Lung Transplant 2000, 19:1071-1076.
75. Cantin B., Giannetti N., Parekh H., et al. Mycophenolic acid concentrations in long-term heart transplant patients: relationship with calcineurin antagonists and acute rejection. Clin Transplant 2002, 16:196-201.
76. Billingham M.E., Cary N.R., Hammond M.E., et al. A working formulation for the standardization of nomenclature in the diagnosis of heart and lung rejection: Heart Rejection Study Group. The International Society for Heart Transplantation. J Heart Transplant 1990, 6:587-593.
77. Ying C., De Clercq E., Neyts J. Ribavirin and mycophenolic acid potentiate the activity of guanine- and diaminopurine-based nucleoside analogues against hepatitis B virus. Antiviral Res 2000, 48:117-124.
78. Teixeira R., Papatheodoridis G.V., Burroughs A.K. Management of recurrent hepatitis C after liver transplantation. J Viral Hepat 2001, 8:159-168.
79. Jain A., Venkataramanan R., Hamad I.S., et al. Pharmacokinetics of mycophenolic acid after mycophenolate mofetil administration in liver transplant patients treated with tacrolimus. J Clin Pharmacol 2001, 41:268-276.
80. Jain A., Kashyap R., Demetric A.J., et al. A prospective randomized control trial of mycophenolate mofetil in liver transplant recipients with hepatitis C. Liver Transpl 2002, 8:40-46.
81. Zmonarski S.C., Boratynska M., Madziarska K., et al. Mycophenolate mofetil severely depresses antibody response to CMV infection in early posttransplant period. Transplant Proc 2003, 35:2205-2206.
82. Aw M.M., Brown N., Itsuka T., et al. Mycophenolic acid pharmacokinetics in pediatric liver transplant recipients. Liver Transpl 2003, 9:383-388.
83. Brown N., Aw M.M., Mieli-Vergani G., et al. Mycophenolic acid and mycophenolic acid glucuronide pharmacokinetics in pediatric liver transplant recipients: effect of cyclosporine and tacrolimus comedication. Ther Drug Monit 2002, 24:598-606.
84. Mardigyan V., Giannetti N., Cecere R., et al. Best single time points to predict the area-under-the-curve in long-term heart transplant patients taking mycophenolate mofetil in combination with cyclosporine or tacrolimus. J Heart Lung Transplant 2005, 24:1614-1618.
85. Dösch A.O., Ehlermann P., Koch A., et al. A comparison of measured trough levels and abbreviated AUC estimation by limited sampling strategies for monitoring mycophenolic acid exposure in stable heart transplant patients receiving cyclosporin A-containing and cyclosporin A-free immunosuppressive regimens. Clin Ther 2006, 28:893-905.
86. Baraldo M., Isola M, Feruglio M.T., et al. Therapeutic mycophenolic acid monitoring by means of limited sampling strategy in orthotopic heart transplantation patients. Transplant Proc 2005, 37:2240-2243.
87. Ting L.S., Partovi N., Levy R.D., et al. Limited sampling strategy for predicting area under the concentration-time curve of mycophenolic acid in adult lung transplant recipients. Pharmacotherapy 2006, 26:1232-1240.
88. Wada K., Takada M., Kotake T., et al. Limited sampling strategy for mycophenolic acid in Japanese heart transplant recipients: comparison of cyclosporin and tacrolimus treatment. Circ J 2007, 71:1022-1028.
89. Kaczmarek I., Bigdeli A.K., Vogeser M., et al. Defining algorithms for efficient therapeutic drug monitoring of mycophenolate mofetil in heart transplant recipients. Ther Drug Monit 2008, 30:419-427.
90. Tsaroucha A.K., Zucker K., Esquenazi V., et al. Levels of mycophenolic acid and its glucuronide derivative in the plasma of liver, small bowel and kidney transplant patients receiving tacrolimus and CellCept combination therapy. Transpl Immunol 2000, 8:143-146.
91. Braun F., Canelo R., Shütz E., et al. How to handle mycophenolate mofetil in combination with tacrolimus?. Transplant Proc 1998, 30:4094-4095.
92. Jain A., Venkataramanan R., Sharma R., et al. Pharmacokinetics of mycophenolic acid in live donor liver transplant patients vs deceased donor liver transplant patients. J Clin Pharmacol 2008, 48:547-552.
93. Kaplan B., Gruber S.A., Nallamathou R., et al. Decreased protein binding of mycophenolic acid associated with leukopenia in a pancreas transplant recipient with renal failure. Transplantation 1998, 65:1127-1129.
94. Benichou A.S., Blanchet B., Conti F., et al. Variability in free mycophenolic acid exposure in adult liver transplant recipients during the early posttransplantation period. J Clin Pharmacol 2010, 50:1202-1210.
95. Pisupati J., Jain A., Burckart G., et al. Intraindividual and interindividual variations in the pharmacokinetics of mycophenolic acid in liver transplant patients. J Clin Pharmacol 2005, 45:34-41.
96. van Hest R., Doodduijn J.K., de Winter B.C.M., et al. Pharmacokinetics of mycophenolate mofetil in haematopoietic stem cell transplant recipients. Ther Drug Monit 2007, 29:353-360.
97. Hesselink D.A., Van Gelder T. Genetic and nongenetic determinants of between-patient variability in the pharmacokinetics of mycophenolic acid. Clin Pharmacol Ther 2005, 78:317-321.
98. Schmidt L.E., Ramussen A., Norelykke M.R., et al. The effect of selective bowel decontamination on the pharmacokinetics of mycophenolate mofetil in liver transplant recipients. Liver Transpl 2001, 7:739-742.
99. Van Gelder T., Klupp J., Barten M.J., et al. Comparison of the effects of tacrolimus and cyclosporine on the pharmacokinetics of mycophenolic acid. Ther Drug Monit 2001, 23:119-128.
100. Lobritto S.J., Rosenthal P., Bouw R., et al. Pharmacokinetics of mycophenolate mofetil in stable pediatric liver transplant recipients receiving mycophenolate mofetil and cyclosporine. Liver Transpl 2007, 13:1570-1575.
101. Picard N., Ratanasavanh D., Premaud A., et al. Identification of the UDP-glucuronosyltransferase isoforms involved in mycophenolic acid phase II metabolism. Drug Metab Dispos 2004, 32:139-146.
102. Girard H., Court M.H., Bernard O., et al. Identification of common polymorphisms in the promoter of the UGT1A9 gene: evidence that UGT1A9 protein and activity levels are strongly genetically controlled in the liver. Pharmacogenet 2004, 14:501-515.
103. Kuypers D.R.J., Naesens M., Vermeire S., et al. The impact of uridine diphosphate-glucuronosyltransferase 1A9 (UGT1A9) gene promoter region single-nucleotide polymorphisms T-275A and C-2152T on early mycophenolic acid dose-interval exposure in de novo renal allograft recipients. Clin Pharmacol Ther 2005, 78:351-361.
104. Kuypers D.R.J., Verleden G., Naesens M., et al. Drug interaction between mycophenolate mofetil and rifampin: possible induction of uridine diphosphate glucuronosyltransferase. Clin Pharmacol Ther 2005, 78:81-88.
105. Djebli N., Picard N., Rerolle J.P., et al. Influence of the UGT2B7 promoter region and exon 2 polymorphisms and comedications on acyl-MPAG production in vitro and in adult renal transplant patients. Pharmacogenet Genomics 2007, 17:321-330.
106. Miura M., Satoh S., Inoue K., et al. Influence of SLCO1B1, 1B3, 2B1 and ABCC2 genetic polymorphisms on mycophenolic pharmacokinetics in Japanese renal transplant recipients. Eur J Clin Pharmacol 2007, 63:1161-1169.
107. Miura M., Kagaya H., Inoue K., et al. Influence of drug transporters and UGT polymorphisms on pharmacokinetics of phenolic glucuronide metabolite of mycophenolic acid in Japanese renal transplant recipients. Ther Drug Monit 2008, 30:559-564.
108. Picard N., Yee S.W., Woillard J.B., et al. The role of organic anion-transporting polypeptides and their common genetic variants in mycophenolic acid pharmacokinetics. Clin Pharmacol Ther 2010, 87:100-108.
109. Satoh S., Tada H., Murakami M., et al. Circadian pharmacokinetics of mycophenolic acid and implication of genetic polymorphisms for early clinical events in renal transplant recipients. Transplantation 2006, 82:486-493.
110. Filler G., Bendrick-Peart J., Christians U. Pharmacokinetics of mycophenolate mofetil and sirolimus in children. Ther Drug Monit 2008, 30:138-142.
111. Strassburg C.P., Strassburg A., Kneip S., et al. Developmental aspects of human hepatic drug glucuronidation in young children and adults. Gut 2002, 50:259-265.
112. Parker G., Bullingham R.E.S., Kamm B., et al. Pharmacokinetics of oral mycophenolate mofetil in volunteer subjects with varying degrees of hepatic oxidative impairment. J Clin Pharmacol 1996, 36:322-338.
113. Shaw L.M., Rosemary M., Nowak I., et al. Pharmacokinetics of mycophenolic acid in renal transplant patients with delayed graft function. J Clin Pharmacol 1998, 38:268-275.
114. Van Gelder T., Shaw L.M. The rationale for and limitations of therapeutic drug monitoring for mycophenolate mofetil in transplantation. Transplantation 2005, 80:S244-253.
115. De Winter B.C.M., Van Gelder T., Sombogaard F., et al. Pharmacokinetic role of protein binding of mycophenolic acid and its glucuronide metabolite in renal transplant recipients. Pharmacokinet Pharmacodyn 2009, 36:541-564.
116. Bullingham R.E.S., Nicholls A.J., Kamm B.R. Clinical pharmacokinetics of mycophenolate mofetil. Clin Pharmacokinet 1998, 34:429-455.
117. Borrows R., Chusney G., Loucaidou M., et al. The magnitude and time course of changes in mycophenolic acid 12-hour predose levels during antibiotic therapy in mycophenolate mofetil-based renal transplantation. Ther Drug Monit 2007, 29:122-126.
118. Naderer O.J., Dupuis R.E., Heinzen E.L., et al. The influence of norfloxacin and metronidazole on the disposition of mycophenolate mofetil. J Clin Pharmacol 2005, 45:219-226.
119. Kofler S., Shvets N., Bigdeli A.K., et al. Proton pump inhibitors reduce mycophenolate exposure in heart transplant recipients-a prospective case-controlled study. Am J Transplant 2009, 9:1650-1656.
120. Hesselink D.A., Van Hest R.M., Mathot R.A.A., et al. Cyclosporine interacts with mycophenolic acid by inhibiting the multidrug resistance-associated protein 2. Am J Transplant 2005, 5:687-694.
121. Cattaneo D., Perico N., Gaspari F., et al. Glucocorticoids interfere with mycophenolate mofetil bioavailability in kidney transplantation. Kidney Int 2002, 62:1060-1067.
122. Naesens M., Kuypers D.R.J., Verbeke K., et al. Multidrug resistance protein 2 genetic polymorphisms influence mycophenolic acid exposure in renal allograft recipients. Transplantation 2006, 82:1074-1084.
123. Annapandian V.M., John G.T., Mathew B.S., et al. Pharmacokinetic interaction between sodium valproate and mycophenolate in renal allograft recipients. Transplantation 2009, 88:1144-1145.
124. Cattaneo D., Bitto A., Baldelli S., et al. Pharmacokinetic/pharmacodynamic drug interaction between rosiglitazone and mycophenolate mofetil in kidney transplantation: a case report. Transplantation 2008, 85:921-922.
125. Perez E.M., J Castroagudin F.S., Rios S.S., et al. Valganciclovir-induced leukopenia in liver transplant recipients: influence of concomitant use of mycophenolate mofetil. Transplant Proc 2009, 41:1047-1049.
126. Mohamed M.E.F., Frye R.F. Inhibition of intestinal and hepatic glucuronidation of mycophenolic acid by Ginkgo biloba extract and flavonoids. Drug Metab Dispos 2010, 38:270-275.
127. Budde K., Bauer S., Hambach P., et al. Pharmacokinetic and pharmacodynamic comparison of enteric-coated mycophenolate sodium and mycophenolate mofetil in maintenance renal transplant recipients. Am J Transplant 2007, 7:888-898.
128. Perry T.W., Christians U., Trotter J.F., et al. Pharmacokinetics of enteric-coated mycophenolate sodium in stable liver transplant recipients. Clin Transplant 2007, 21:413-416.
129. Hummel M., Yonan N., Ross H., et al. Pharmacokinetics and variability of mycophenolic acid from enteric-coated mycophenolate sodium compared with mycophenolate mofetil in de novo heart transplant recipients. Clin Transplant 2007, 21:18-23.
130. de Winter B.C.M., Van Gelder T., Mathot R.A.A., et al. Limited sampling strategies drawn within 3 hours post dose poorly predict mycophenolic acid area-under-the-curve after enteric-coated mycophenolate sodium. Ther Drug Monit 2009, 31:585-591.
131. Shaw L.M., Holt D.W., Oellerich M., et al. Current issues in therapeutic drug monitoring of mycophenolic acid: report of a roundtable discussion. Ther Drug Monit 2001, 23:305-315.
132. Jacobson P., Rogosheske J., Barker J.N., et al. Relationship of mycophenolic acid exposure to clinical outcome after hematopoietic cell transplantation. Clin Pharmacol Ther 2005, 78:486-500.
133. Mardigyan V., Tchervenkov J., Metrakos P., et al. Best single time points as surrogates to the tacrolimus and mycophenolic acid area under the curve in adult liver transplant patients beyond 12 months of transplantation. Clin Ther 2005, 27:463-469.
134. Schütz E., Shipkova M., Armstrong V.W., et al. Identification of a pharmacologically active metabolite of mycophenolic acid in plasma of transplant recipients treated with mycophenolate mofetil. Clin Chem 1999, 45:419-422.
135. Brandhorst G., Marquet P., Shaw L.M., et al. Multicenter evaluation of a new inosine monophosphate dehydrogenase inhibition assay for quantification of total mycophenolic acid in plasma. Ther Drug Monit 2008, 30:428-433.
136. Heller T., van Gelder T., Budde K., et al. Plasma concentrations of mycophenolic acid acyl glucuronide are not associated with diarrhea in renal transplant patients. Am J Transplant 2007, 7:1822-1831.
137. Shipkova M., Armstrong V.W., Weber L., et al. Pharmacokinetics and protein adduct formation of the pharmacologically active acyl glucuronide metabolite of mycophenolic acid in pediatric renal transplant recipients. Ther Drug Monit 2002, 24:390-399.
138. Tracey J., Brown N.W., Tredger J.M. Evaluation of mycophenolic acid stability in plasma and whole blood 2009.